May 4, 2023

## VIA EDGAR

United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes

Re: Lexaria Bioscience Corp Registration Statement on Form S-1, as amended Initially filed on April 3, 2023, as amended on April 28, 2023 File No. 333-271096 (the "*Registration Statement*") Withdrawal Request for Acceleration

Ladies and Gentlemen:

We hereby request the withdrawal of our request for acceleration, dated May 3, 2023, of the effective date of the Registration Statement on Form S-1, as amended (File No. 333-271096) that was requested to become effective at 9:00 a.m. Eastern Time, on May 5, 2023, or as soon thereafter as practicable. We hereby respectfully withdraw this acceleration request at this time.

Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Sichenzia Ross Ference LLP, attention: Avital Perlman, Esq. at (212) 930-9700.

Very truly yours,

By:

LEXARIA BIOSCIENCE CORP

/s/ Christopher Bunka Christopher Bunka Chief Executive Officer